The Pennant Group (NASDAQ:PNTG) Announces FY 2026 Earnings Guidance

The Pennant Group (NASDAQ:PNTG) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided earnings per share guidance of 1.340-1.410 for the period, compared to the consensus EPS estimate of 1.360. The company issued revenue guidance of $1.2 billion, compared to the consensus revenue estimate of $1.2 billion.

The Pennant Group Stock Down 9.1%

PNTG stock opened at $36.36 on Friday. The company has a current ratio of 1.20, a quick ratio of 1.20 and a debt-to-equity ratio of 0.48. The Pennant Group has a 1-year low of $23.50 and a 1-year high of $44.24. The company’s 50 day moving average is $40.16 and its 200 day moving average is $35.70. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of 36.73, a price-to-earnings-growth ratio of 2.64 and a beta of 1.33.

The Pennant Group (NASDAQ:PNTG) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $0.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.01). The company had revenue of $302.25 million for the quarter, compared to analysts’ expectations of $299.34 million. The Pennant Group had a net margin of 2.93% and a return on equity of 10.33%. Sell-side analysts predict that The Pennant Group will post 1.18 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on PNTG shares. Royal Bank Of Canada lifted their price objective on The Pennant Group from $44.00 to $48.00 and gave the company an “outperform” rating in a report on Friday. Weiss Ratings raised The Pennant Group from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, August 19th. Truist Financial raised their price objective on shares of The Pennant Group from $42.00 to $48.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Oppenheimer raised their price objective on The Pennant Group from $47.00 to $50.00 and gave the company an “outperform” rating in a report on Thursday. Finally, Wall Street Zen cut The Pennant Group from a “buy” rating to a “hold” rating in a research report on Saturday. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $48.00.

The Pennant Group News Roundup

Here are the key news stories impacting The Pennant Group this week:

• Positive Sentiment: RBC raised its price target to $48 from $44 and maintained an Outperform rating. RBC Raises Price Target on Pennant Group
• Positive Sentiment: Oppenheimer also lifted its target, to $50 from $47, and reiterated an Outperform rating—suggesting continued analyst confidence in the company’s prospects.
• Positive Sentiment: Q3 coverage said Pennant beat earnings and sales expectations, a supportive signal for demand and financial performance. Pennant Group Earnings Beat Pennant Group Beats Q3 Sales Expectations
• Neutral Sentiment: For FY 2026, Pennant guided to EPS of $1.34–$1.41, straddling the $1.36 consensus, and revenue of $1.2 billion, in line with expectations. The range offers limited upside versus consensus, while its lower end is below it.
• Negative Sentiment: A Q3 analysis highlighted margin pressure and integration challenges as risks to the outlook. These concerns may temper the impact of the earnings beat and analyst target increases. Q3 Deep Dive: Margin Pressure and Integration Challenges

About The Pennant Group

The Pennant Group, Inc is a healthcare services company that operates home health, hospice and senior living businesses in the United States. Through its affiliated agencies and communities, the company provides skilled nursing, physical, occupational and speech therapy, personal care, hospice and palliative services, assisted living, and other support for older adults and individuals recovering from illness or injury.

Pennant’s home health and hospice operations serve patients in their homes and other residential settings, while its senior living segment operates communities that provide assisted living and related services.